1. Barbeau, A., Roy, M., Kastin, A. J.: Double-blind evaluation of oral l-prolyl-l-leucyl-glycine amide in Parkinson's disease. Canad. med. Ass. J. 114, 120?122 (1976)
2. Björkman, S., Castensson, S., Lindeke, B., Sievertsson, H.: Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. Acta pharm. suec. 13, 289?298 (1976)
3. Castensson, S., Sievertsson, H., Lindeke, B., Sum, C. Y.: Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides. FEBS Letters 44, 101?105 (1974)
4. Dixon, W. J.: The up-and-down method for small samples. J. Amer. statist. Ass. 60, 967?978 (1965)
5. Fischer, P.-A., Schneider, E., Jacobi, P., Maxion, H.: Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom. Europ. Neurol. 12, 360?368 (1974)